These press releases are for business and financial media.
-
- 31 August 2003
- European Society of Cardiology (ESC) Congress, Vienna. Charm Media briefing Candesartan in heart failure: effects on mortality and morbidity. An AstraZeneca sponsored symposium held during the meeting of the ESC Congress 2003 in Vienna, Austria 30 August - 3 September 2003.
-
- 27 August 2003
- ASTRAZENECA INTRODUCES INTRAVENOUS FORMULATION OF NEXIUM® (esomeprazole) IN FIRST MARKET - SWEDEN Offering New Hope to Patients Unable to Take Oral PPI Therapy AstraZeneca announced today, after receiving its first approval from the Swedish Medical Products Agency (MPA), that it will launch the new intravenous (i.v.) formulation of the proton pump inhibitor (PPI) Nexium®, providing an opportunity for physicians to treat patients suffering from gastroesophageal reflux disease (GERD) who are unable to take oral therapy. Nexium® administered intravenously demonstrates the same efficacy as oral Nexium®
-
- 15 August 2003
- New data add to the growing evidence of gefitinib's New data support gefitinib (IRESSA TM , ZD1839) as an efficacious anti-cancer agent in patients with non-small cell lung cancer World Conference on Lung Cancer, Vancouver, 14 August 2003 – New data add to the growing evidence of gefitinib’s (IRESSA TM , ZD1839) efficacy and well-established safety profile and reinforce its current and future role as a leading targeted treatment in the fight against non-small cell lung cancer (NSCLC). Data from the Phase ll IDEAL* studies 1 reveal patients with advanced
-
- 13 August 2003
- CRESTOR® RECEIVES FDA APPROVAL CRESTOR Significantly Lowers LDL Cholesterol by As Much As 63% AstraZeneca announced today that its new cholesterol-lowering medication, CRESTOR® (rosuvastatin calcium), which has been shown to lower LDL-cholesterol by up to 63 percent, has received approval from the U.S. Food and Drug Administration (FDA) as an adjunct to diet for the treatment of various lipid disorders including primary hypercholesterolemia, mixed dyslipidemia and isolated hypertriglyceridemia. This follows the successful Advisory
-
- 08 August 2003
- ASTRAZENECA TO SEEK TRIPLE DAMAGES IN PATENT INFRINGEMENT LAWSUIT AGAINST MYLAN PHARMACEUTICALS AstraZeneca announced today that it will amend its lawsuit against Mylan Pharmaceuticals to seek triple damages for the wilful and intentional infringement of AstraZeneca’s Prilosec® (omeprazole) formulation patents. In addition, AstraZeneca is filing suit to recover wilful infringement damages against Esteve Quimica, S.A. and Laboratorios Dr. Esteve, S.A., which are formulators of the Mylan omeprazole product. AstraZeneca reaffirms its commitment to vigorously defend its right to patent protection both
-
- 06 August 2003
- What treatment next for postmenopausal breast cancer patients London, UK – Wednesday 6 August 2003: AstraZeneca announced today that patient recruitment has begun on an important new trial involving its novel estrogen receptor antagonist, ‘Faslodex’ (fulvestrant). The trial, called EFECT*, is designed to answer one of the most important questions emerging in the treatment of breast cancer– which hormonal therapy will provide the best outcome for postmenopausal patients with early or advanced breast cancer whose disease has recurred or progressed on treatment with
-
- 31 July 2003
- ASTRAZENECA REFUTES PRELIMINARY FINDINGS OF EC OMEPRAZOLE INVESTIGATION AstraZeneca confirms that the European Commission has served a ‘Statement of Objections’ on the company, stating that in the Commission’s preliminary view AstraZeneca abused its dominant position with omeprazole (‘Losec’) in a number of European countries and that this would constitute an infringement of Article 82 of the EU Treaty. AstraZeneca intends to respond to the Statement and the company vigorously refutes any wrongdoing. In particular AstraZeneca will deny that it made misrepresentations
-
- 24 July 2003
- ASTRAZENECA PLC SECOND QUARTER AND HALF YEAR RESULTS 2003 “First half results ahead of expectations. Interim dividend increased by 10 percent. EPS targets for the year increased.”
-
- 18 July 2003
- ASTRAZENECA DONATES £60,000 FOR MEDICAL TEXT BOOKS IN THE DEVELOPING WORLD AstraZeneca announced today that it will provide a £60,000, four-year grant to BookPower, a non-profit organisation which provides medical and nursing text books at a subsidised price to students in Africa. The AstraZeneca grant will be used to fund medical texts covering the subjects of Cardiology, Endocrinology, Gastroenterology, Immunology and Infection.
-
- 15 July 2003
- Clinical Response to Gefitinib (IRESSA™, ZD1839) in patients with Advanced NSCLC* Bears no Consistent Relation to EGFR* Status AACR: The clinical efficacy of AstraZeneca’s novel anti-cancer treatment gefitinib (IRESSA™, ZD1839) does not appear to have a consistent association of relevance with membrane expression level of EGFR (Epidermal Growth Factor Receptor) in patients with advanced non-small cell lung cancer (NSCLC), according to new research 1 presented at this year’s American Association of Cancer Research (AACR) congress, Washington, United States.
-
- 14 July 2003
- Exanta™ (ximelagatran) shows efficacy in first pivotal study for treatment of venous thromboembolism (VTE) 14th July, 2003, XIX Congress of the International Society on Thrombosis and Haemostasis (ISTH), Birmingham, UK: Data from the THRIVE Treatment study, presented today, show that Exanta™ (ximelagatran), the first in a new class of oral anticoagulants called oral direct thrombin inhibitors (oral DTIs), is as effective as the current standard of care treatment regimen, enoxaparin/warfarin, in the treatment of acute venous thromboembolism (VTE; deep vein thrombosis with or without pulmonary embolism) and
-
- 14 July 2003
- EXANTA™(ximelagatran) SHOWS EFFICACY IN FIRST STUDY FOR TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) – SUPPORTS REGULATORY SUBMISSION AstraZeneca announced today that data from the THRIVE Treatment study show that Exanta™ (ximelagatran), the first in a new class of oral anticoagulants called oral direct thrombin inhibitors (oral DTIs), is as effective as the current standard of care treatment regimen, enoxaparin/warfarin, in the treatment of acute venous thromboembolism (VTE; deep vein thrombosis with or without pulmonary embolism) and secondary prevention of recurrent VTE events. Importantly, the six month long study, presented today at
-
- 10 July 2003
- FDA ADVISORY COMMITTEE UNANIMOUSLY RECOMMENDS APPROVAL OF CRESTOR® (rosuvastatin calcium) AstraZeneca announced today that the Endocrinologic and Metabolic Advisory Committee to the U.S. Food and Drug Administration (FDA) unanimously voted to recommend approval for CRESTOR® (rosuvastatin calcium) as an adjunct to diet for the treatment of various lipid disorders including hypercholesterolemia, mixed dyslipidemia and isolated hypertriglyceridemia. The FDA will now review the Committee’s recommendation and make its final decision on granting marketing approval for CRESTOR.
-
- 04 July 2003
- EARLY INTERVENTION WITH ATACAND® IMPROVES OUTCOME FOR PATIENTS WITH ACUTE ISCHAEMIC STROKE (London, Friday 4 July 2003) - In the ACCESS* trial Atacand ® (candesartan cilexetil**) reduced the number of vascular events by 45% during 12 months following acute stroke in patients with elevated blood pressure.
-
- 01 July 2003
- ASTRAZENECA PLC APPOINTS TWO NEW NON-EXECUTIVE DIRECTORS AstraZeneca PLC today announced that two new Non-Executive Directors are to join the Board of Directors with immediate effect.
-
- 23 June 2003
- ASTRAZENECA ANNOUNCES ABSTRACT PUBLISHED ON EXANTA™ (ximelagatran) IN THE TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) AstraZeneca today announced the publication of an abstract, which details the results from the phase III THRIVE Treatment study (1) for Exanta™ (ximelagatran), the first of a new class of oral direct thrombin inhibitor (oral DTI). The results of the THRIVE Treatment study will be presented at the XIX Congress of the International Society on Thrombosis and Haemostasis, on Monday 14 July 2003. The abstract is available online at: http://www.isth2003.co.uk/ Top line results include:
-
- 20 June 2003
- ASTRAZENECA ANNOUNCES SETTLEMENT WITH U.S. GOVERNMENT ON ZOLADEX® INVESTIGATION AstraZeneca today announced the settlement of a multi-year investigation into US sales and marketing practices for Zoladex® (goserelin acetate implant), a treatment for prostate cancer.
-
- 16 June 2003
- ASTRAZENECA OPENS NEW US$25M (£16M) PHARMACEUTICAL R&D FACILITY FOR INVESTIGATIONAL PRODUCTS AT MACCLESFIELD, CHESHIRE, UK New research and development (R&D) facilities, worth around US$25 million (£16 million), were officially opened today at AstraZeneca’s Macclesfield site by the Company’s Executive VP Global Development, Dr Martin Nicklasson.
-
- 02 June 2003
- ASTRAZENECA OPENS MULTI-MILLION DOLLAR INDIAN RESEARCH FACILITY TO FIND NEW TREATMENTS FOR TUBERCULOSIS AstraZeneca today opened a new multi-million dollar research facility in Bangalore, India, which will focus principally on finding new treatments for tuberculosis (TB), a disease which is diagnosed in about two million people every year in India and in more than eight million people worldwide, mostly in the developing world (WHO Report 2003). At the opening, Sir Tom McKillop, Chief Executive, AstraZeneca PLC, highlighted AstraZeneca’s unique commitment to India, which combines TB research and manufacturing
-
- 02 June 2003
- IRESSA™ (gefitinib) DEMONSTRATES CLINICAL ACTIVITY IN MULTIPLE TUMOUR TYPES AstraZeneca announced today that new data presented at the 39th American Society of Clinical Oncology Annual Meeting in Chicago demonstrate the potential of IRESSA™ (gefitinib, ZD1839) to have anti-tumour activity across a broad range of common cancers. Encouraging data from Phase ll trials in advanced colorectal cancer, non-small cell lung cancer (NSCLC), breast cancer and brain cancer support IRESSA’s current and future role as an efficacious anti-cancer agent that is generally well tolerated across all
-
- 22 May 2003
- ASTRAZENECA OPENS NEW US$145M (£90M) BULK MANUFACTURING FACILITIES FOR CRESTOR® AT AVLON WORKS, BRISTOL, UK New bulk drug manufacturing facilities, worth a total of around US$145 million (£90 million), were officially opened today at AstraZeneca’s Avlon Works near Bristol by the Company’s Deputy Chairman, Dr Håkan Mogren.
-
- 21 May 2003
- NEW DATA SHOW NEXIUM® RELIEVES NSAID RELATED UPPER GI SYMPTOMS IN PATIENTS WITHOUT ULCERS AstraZeneca announced today that new data, presented at the annual Digestive Diseases Week Meeting in Orlando, Florida, show that NEXIUM® (esomeprazole) is the first Proton Pump Inhibitor (PPI) proven to significantly relieve upper gastrointestinal (GI) symptoms in non-steroidal anti-inflammatory drug (NSAID) users without ulcers.
-
- 21 May 2003
- NEW DATA SHOW SEROQUEL® TO BE AN EFFECTIVE, WELL-TOLERATED AND FAST-ACTING TREATMENT FOR MANIA IN BIPOLAR DISORDER AstraZeneca today announced new data, presented at the 156th annual meeting of the American Psychiatric Association (APA) in San Francisco, which indicate that SEROQUEL® (quetiapine) is effective, well tolerated and fast-acting when used as monotherapy for the treatment of mania associated with bipolar disorder.
-
- 20 May 2003
- CRESTOR® - NEW DATA AND REGULATORY UPDATE New Data
-
- 05 May 2003
- ASTRAZENECA RECEIVES FDA APPROVAL FOR NEW CANCER DRUG IRESSA™ (gefitinib, ZD1839) IRESSA is the First in a New Class of Drugs for the Treatment of Advanced Non-Small Cell Lung Cancer - Only FDA-Approved Option for Third Line Patients
-
- 01 May 2003
- ASTRAZENECA RECEIVES AUSTRALIAN APPROVAL FOR IRESSA™ FOR ADVANCED NON-SMALL CELL LUNG CANCER - Second Approval for Novel Anti-cancer Treatment AstraZeneca announced today that the Australian Therapeutic Goods Administration has granted approval of IRESSA™ (gefitinib, ZD1839) for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have previously received treatment with chemotherapy. The decision in Australia represents the second approval world-wide for IRESSA— the first in a new class of anti-cancer drugs known as ‘Epidermal Growth Factor Receptor (EGFR) inhibitors’. IRESSA was approved by the
-
- 30 April 2003
- ASTRAZENECA PLC - ANNUAL GENERAL MEETING : 30 APRIL 2003 AstraZeneca PLC announced the results of the polls taken at its Annual General Meeting today in respect of Items 5(e), 9 and 10 on the Agenda, as follows:
-
- 30 April 2003
- AstraZeneca PLC: Håkan Mogren to become Non-Executive Director AstraZeneca PLC announced today that Dr Håkan Mogren, currently Executive Deputy Chairman, will cease to be an Executive Director of the Company on 31 August 2003. With effect from that date, he will become Non-Executive Deputy Chairman.
-
- 30 April 2003
- First Quarter Results 2003 Download the narrative and the figures .
-
- 03 April 2003
- ASTRAZENECA AND ADVENT INTERNATIONAL FORM STRATEGIC PARTNERSHIP AstraZeneca UK Limited announced today the initiation of a strategic relationship with Advent International Corporation for the purpose of identifying and evaluating emerging technologies in health care and life sciences. Representatives from AstraZeneca’s Discovery and Business Development groups will work closely with Advent’s Boston-based health care team in evaluating emerging opportunities and transactions with companies in the health care and life sciences industry.
Not signed in
Page tools
Share price
- London
-
28.32 GBP - New York
-
44.19 USD
- Stockholm
-
326.30 SEK
At 09-Feb-2010 15:05 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
